Literature DB >> 19345584

Ribonuclear inclusions and MBNL1 nuclear sequestration do not affect myoblast differentiation but alter gene splicing in myotonic dystrophy type 2.

Rosanna Cardani1, Simona Baldassa, Annalisa Botta, Fabrizio Rinaldi, Giuseppe Novelli, Enzo Mancinelli, Giovanni Meola.   

Abstract

Myotonic dystrophy type 2 (DM2) is an autosomal dominant multisystemic disorder caused by a CCTG expansion in intron 1 of the zinc finger protein 9 gene on chromosome 3. Mutant transcripts are retained in muscle nuclei producing ribonuclear inclusions, which can bind specific RNA-binding proteins leading to a reduction in their activity. The nuclear sequestration of muscleblind-like proteins appears to be involved in splicing defects of genes directly related to the myotonic dystrophy phenotypes. Experimental evidence suggests that ribonuclear inclusions and muscleblind-like protein 1 (MBNL1) sequestration are strongly involved in DM2 pathogenesis. By using fluorescence in situ hybridization in combination with MBNL1-immunofluorescence, we have observed the presence of ribonuclear inclusions and MBNL1 nuclear sequestration at different time points of in vitro myoblast differentiation in each DM2 patient examined. Immunofluorescence and Western blot analysis of several markers of skeletal muscle differentiation reveal that the degree of differentiation of DM2 myoblasts is comparable to that observed in controls. Nevertheless the splicing pattern of the insulin receptor and MBNL1 transcripts, directly related to the DM2 phenotype, appears to be altered in in vitro differentiated DM2 myotubes. Our data seem indicate that the presence of ribonuclear inclusions and MBNL1 nuclear foci are involved in alteration of alternative splicing but do not impair DM2 myogenic differentiation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19345584     DOI: 10.1016/j.nmd.2009.03.002

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  15 in total

Review 1.  Myotonic dystrophy type 2 and modifier genes: an update on clinical and pathomolecular aspects.

Authors:  Giovanni Meola; Rosanna Cardani
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

2.  Aberrant Myokine Signaling in Congenital Myotonic Dystrophy.

Authors:  Masayuki Nakamori; Kohei Hamanaka; James D Thomas; Eric T Wang; Yukiko K Hayashi; Masanori P Takahashi; Maurice S Swanson; Ichizo Nishino; Hideki Mochizuki
Journal:  Cell Rep       Date:  2017-10-31       Impact factor: 9.423

3.  Human Sarcopenic Myoblasts Can Be Rescued by Pharmacological Reactivation of HIF-1α.

Authors:  Federica Cirillo; Laura Mangiavini; Paolo La Rocca; Marco Piccoli; Andrea Ghiroldi; Paola Rota; Adriana Tarantino; Barbara Canciani; Simona Coviello; Carmelo Messina; Giuseppe Ciconte; Carlo Pappone; Giuseppe Maria Peretti; Luigi Anastasia
Journal:  Int J Mol Sci       Date:  2022-06-26       Impact factor: 6.208

4.  Cultured myoblasts from patients affected by myotonic dystrophy type 2 exhibit senescence-related features: ultrastructural evidence.

Authors:  M Malatesta; M Giagnacovo; L V Renna; R Cardani; G Meola; C Pellicciari
Journal:  Eur J Histochem       Date:  2011-08-27       Impact factor: 3.188

5.  Premature senescence in primary muscle cultures of myotonic dystrophy type 2 is not associated with p16 induction.

Authors:  L V Renna; R Cardani; A Botta; G Rossi; B Fossati; E Costa; G Meola
Journal:  Eur J Histochem       Date:  2014-10-22       Impact factor: 3.188

6.  Myotonic Dystrophy Type 2: An Update on Clinical Aspects, Genetic and Pathomolecular Mechanism.

Authors:  Giovanni Meola; Rosanna Cardani
Journal:  J Neuromuscul Dis       Date:  2015-07-22

7.  Receptor and post-receptor abnormalities contribute to insulin resistance in myotonic dystrophy type 1 and type 2 skeletal muscle.

Authors:  Laura Valentina Renna; Francesca Bosè; Sara Iachettini; Barbara Fossati; Lorenzo Saraceno; Valentina Milani; Roberto Colombo; Giovanni Meola; Rosanna Cardani
Journal:  PLoS One       Date:  2017-09-15       Impact factor: 3.240

8.  A flow cytometry-based screen identifies MBNL1 modulators that rescue splicing defects in myotonic dystrophy type I.

Authors:  Fan Zhang; Nicole E Bodycombe; Keith M Haskell; Yumei L Sun; Eric T Wang; Carl A Morris; Lyn H Jones; Lauren D Wood; Mathew T Pletcher
Journal:  Hum Mol Genet       Date:  2017-08-15       Impact factor: 6.150

9.  rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences.

Authors:  Chantal Sellier; Estefanía Cerro-Herreros; Markus Blatter; Fernande Freyermuth; Angeline Gaucherot; Frank Ruffenach; Partha Sarkar; Jack Puymirat; Bjarne Udd; John W Day; Giovanni Meola; Guillaume Bassez; Harutoshi Fujimura; Masanori P Takahashi; Benedikt Schoser; Denis Furling; Ruben Artero; Frédéric H T Allain; Beatriz Llamusi; Nicolas Charlet-Berguerand
Journal:  Nat Commun       Date:  2018-05-22       Impact factor: 14.919

Review 10.  RNA/MBNL1-containing foci in myoblast nuclei from patients affected by myotonic dystrophy type 2: an immunocytochemical study.

Authors:  F Perdoni; M Malatesta; R Cardani; M Giagnacovo; E Mancinelli; G Meola; C Pellicciari
Journal:  Eur J Histochem       Date:  2009-09-30       Impact factor: 3.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.